Correction: Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia

Key Points

• To address the relationship between elevated IL-17A levels and overall survival in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors and targeted therapies.
• Correction of previously presented results regarding IL-17A levels and overall survival
• Focused on patients with hepatocellular carcinoma and hyperbilirubinemia
• Examined effects of combination therapy with immune checkpoint inhibitors and targeted therapy.
• Higher levels of IL-17A correlate with reduced overall survival rates among affected patients.
• Findings imply significant clinical consequences for treatment strategies in this patient population.